Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [14C]aficamten following single oral dose administration to rats

The pharmacokinetics, metabolism, excretion, mass balance, and tissue distribution of [C-14]aficamten were evaluated following oral administration of an 8 mg/kg dose in Sprague Dawley rats and in a quantitative whole-body autoradiography study in Long Evans rats.<br /> [C-14]Aficamten accounted for similar to 80% and a hydroxylated metabolite (M1) accounted for similar to 12% of total radioactivity in plasma over 48-h (AUC(0-48)). Plasma t(max) was 4-h and the t(1/2) of total plasma radioactivity was 5.8-h.<br /> Tissues showing highest C-max exposures were myocardium and semitendinosus muscle.<br /> Most [C-14]aficamten-derived radioactivity was excreted within 48-h post-administration. Mean cumulative recovery in urine and faeces over 168-h was 8.3% and 90.7%, respectively.<br /> In urine and bile, unchanged aficamten was detected at <0.1 and <0.2% of dose, respectively; however, based on total radioactivity excreted in urine (8.0%) and bile (51.7%), approximately 60% of dose was absorbed.<br /> [C-14]Aficamten was metabolised by hydroxylation with subsequent glucuronidation where the most abundant metabolite recovered in bile was M5 (35.2%), the oxygen-linked glucuronide of hydroxylated aficamten (M1a). The major metabolite detected in faeces was a 1,2,4-oxadiazole moiety ring-cleaved metabolite (M18, 35.3%), shown to be formed from the metabolism of M5 in incubations with rat intestinal contents solution.